ALSO NOTED: GW Pharma must mount new trials; Elan shares surge on Tysabri strategy; and much more...

> GW Pharma confirmed reports that regulators will require the company to mount new clinical trials to confirm the safety of its cannabis-based Sativex. Story

> Shares of Elan and Biogen Idec surged late Thursday after the New England Journal fo Medicine quoted doctors for Biogen discussing strategies to return Tysabri to the market while protecting patients from a possible brain infection. Story

> The European Commission has approved Schering-Plough's Temodal for first-line use for the treatment of newly diagnosed glioblastoma multiforme, the most common and aggressive form of primary brain cancer. Release

> The FDA has extended its review of Insmed's Somatokine for three months, until October 3. Release

And Finally... Drug makers believe a proposed new law on patents could make life harder for the industry. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.